{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:46:25Z","timestamp":1743266785110,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To determine the effectiveness of golimumab (GLM) in improving joint, periarticular structures and cutaneous manifestations in patients with moderate to severe psoriatic arthritis (PsA) with cutaneous psoriasis in different real-life clinical settings and 48-month drug survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical and laboratory records were collected from PsA patients treated with GLM at baseline (T0) and after 6, 12, 24, 36, and 48\u00a0months of treatment. Comparisons were performed using a paired <jats:italic>t<\/jats:italic>-test or Wilcoxon test. Drug survival rates were analyzed using Kaplan\u2013Meier estimates. <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.05 was considered statistically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 105 patients were collected. PsO occurred in 80% of patients and enthesitis in 78%, peripheral and axial arthritis in 63.8% and 35.3%, respectively, while erosions in 36.2%. The main comorbidities were cardiovascular diseases (31.4%) and metabolic syndrome (MetS) (19%). A statistically significant improvement in articular and cutaneous psoriasis was registered at T48 of GLM-therapy in clinical (DAPSA <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001; PASI <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01; BASDAI <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and laboratory (CRP\u2009&lt;\u20090.05) indexes. Gender (<jats:italic>p<\/jats:italic>\u2009=\u20090.652), BMI (<jats:italic>p<\/jats:italic>\u2009=\u20090.655), smoking habit (<jats:italic>p<\/jats:italic>\u2009=\u20090.466), and line of treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.208) did not affect treatment efficacy nor persistence. At T48, 42% of patients discontinued GLM: the most frequent reason was an insufficient response or loss of efficacy (28.6%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A 48-month GLM high drug persistence of PsA patients was observed in real-life, in patients presenting high disease activity, elevated prevalence of comorbidities, and more than one line of treatment at baseline. Patients\u2019 characteristics as gender, smoke, BMI, different lines of treatment, and concomitant methotrexate treatment affected treatment persistence, making GLM effective and safe in moderate-severe PsA in a long-term real-life setting.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Golimumab was effective in psoriatic arthritis, including both musculoskeletal and cutaneous manifestations. <\/jats:italic>\u2022 <jats:italic>Golimumab effectiveness and drug survival were not affected by comorbidities and patient-related characteristics. <\/jats:italic>\u2022 <jats:italic>The 4-year drug survival curves confirm the efficacy and safety of golimumab in psoriatic arthritis patients in a real-life setting. <\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-021-05874-6","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T07:03:20Z","timestamp":1629356600000},"page":"75-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1729","authenticated-orcid":false,"given":"Maria Sole","family":"Chimenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Conigliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Triggianese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia Lavinia","family":"Fonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Lorenzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"5874_CR1","first-page":"1046","volume":"38","author":"E Calabresi","year":"2020","unstructured":"Calabresi E, Monti S, Terenzi R, Zanframundo G, Perniola S, Carli L (2020) One year in review 2019: psoriatic arthritis. Clin Exp Rheumatol 38:1046\u20131055","journal-title":"Clin Exp Rheumatol"},{"key":"5874_CR2","doi-asserted-by":"publisher","first-page":"204062231984705","DOI":"10.1177\/2040622319847056","volume":"10","author":"MS Chimenti","year":"2019","unstructured":"Chimenti MS, Esposito M, Graceffa D, Teoli M, Peluso G, Birra D et al (2019) PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. Ther Adv Chronic Dis 10:2040622319847056. https:\/\/doi.org\/10.1177\/2040622319847056","journal-title":"Ther Adv Chronic Dis"},{"key":"5874_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05482","author":"E Lubrano","year":"2019","unstructured":"Lubrano E, Delle Sedie A, Romanelli M, Chimenti MS, Bianchi L, Piaserico S et al (2019) Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-020-05482","journal-title":"Clin Rheumatol"},{"key":"5874_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/1744666X.2019.1627876","volume":"15","author":"MS Chimenti","year":"2019","unstructured":"Chimenti MS, Triggianese P, De Martino E, Conigliaro P, Fonti GL, Sunzini F et al (2019) An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Rev Clin Immunol 15:823\u2013836. https:\/\/doi.org\/10.1080\/1744666X.2019.1627876","journal-title":"Expert Rev Clin Immunol"},{"key":"5874_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/BTT.S260754","volume":"14","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, D\u2019Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, Perricone R (2020) An update for the clinician on biologics for the treatment of psoriatic arthritis. Biologics 14:53\u201375. https:\/\/doi.org\/10.2147\/BTT.S260754","journal-title":"Biologics"},{"key":"5874_CR6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3389\/fphar.2019.01497","volume":"10","author":"S D'Angelo","year":"2019","unstructured":"D\u2019Angelo S, Cantini F, Ramonda R, Cantarini L, Carletto A, Chimenti MS et al (2019) Effectiveness of adalimumab for the treatment of psoriatic arthritis: an Italian real-life retrospective study. Front Pharmacol 10:1497. https:\/\/doi.org\/10.3389\/fphar.2019.01497","journal-title":"Front Pharmacol"},{"key":"5874_CR7","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/simponi"},{"key":"5874_CR8","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A (2014) Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 73:1689\u20131694. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204902","journal-title":"Ann Rheum Dis"},{"key":"5874_CR9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW et al (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060\u20131071. https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheumatol"},{"key":"5874_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000354263","volume":"227","author":"MS Chimenti","year":"2013","unstructured":"Chimenti MS, Teoli M, Saraceno R, Dattola A, Ventura A, Chiricozzi A, Chiaramonte C, Perricone R, Chimenti S (2013) Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology 227:305\u2013310. https:\/\/doi.org\/10.1159\/000354263","journal-title":"Dermatology"},{"key":"5874_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.07.011","volume":"88","author":"F Iannone","year":"2020","unstructured":"Iannone F, Favalli EG, Caporali R, D\u2019Angelo S, Cantatore FP, Sarzi-Puttini P et al (2020) Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine 88:105062. https:\/\/doi.org\/10.1016\/j.jbspin.2020.07.011","journal-title":"Joint Bone Spine"},{"key":"5874_CR12","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665\u201373. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"key":"5874_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","volume":"31","author":"P Gisondi","year":"2017","unstructured":"Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A et al (2017) Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 31:774\u2013790. https:\/\/doi.org\/10.1111\/jdv.14114","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5874_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"5874_CR15","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640\u20131645. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192644","journal-title":"Circulation"},{"key":"5874_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.semarthrit.2021.03.007","volume":"51","author":"J Feld","year":"2021","unstructured":"Feld J, Ye JY, Chandran V et al (2021) Axial disease in psoriatic arthritis: the presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. Semin Arthritis Rheum 51:464\u2013468. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.03.007","journal-title":"Semin Arthritis Rheum"},{"key":"5874_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fimmu.2019.00305","volume":"10","author":"WP Maksymowych","year":"2019","unstructured":"Maksymowych WP (2019) Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front Immunol 10:305. https:\/\/doi.org\/10.3389\/fimmu.2019.00305","journal-title":"Front Immunol"},{"key":"5874_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-018-4324-7","volume":"38","author":"\u017d Rotar","year":"2019","unstructured":"Rotar \u017d, Tom\u0161i\u010d M, Praprotnik S, Rheumatologists S (2019) The persistence of golimumab compared to other tumour necrosis factor-\u03b1 inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Clin Rheumatol 38:297\u2013305. https:\/\/doi.org\/10.1007\/s10067-018-4324-7","journal-title":"Clin Rheumatol"},{"key":"5874_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025223","volume":"100","author":"JJ Alegre-Sancho","year":"2021","unstructured":"Alegre-Sancho JJ, Juanola X, Rodr\u00edguez-Heredia JM, Manero J, Villa-Blanco I, Laiz A, Arteaga MJ, Cea-Calvo L, Gonz\u00e1lez CM (2021) Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: a retrospective study. Medicine (Baltimore) 100:e25223. https:\/\/doi.org\/10.1097\/MD.0000000000025223","journal-title":"Medicine (Baltimore)"},{"key":"5874_CR20","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM et al (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"5874_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00296-018-4194-y","volume":"39","author":"L Jacob","year":"2019","unstructured":"Jacob L, Chevalier T, Kostev K (2019) Persistence with biological drugs in patients treated in rheumatology practices in Germany. Rheumatol Int 39(3):525\u2013531","journal-title":"Rheumatol Int"},{"key":"5874_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","volume":"17","author":"L Costa","year":"2017","unstructured":"Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R et al (2017) Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D 17:509\u2013522","journal-title":"Drugs R D"},{"key":"5874_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","volume":"23","author":"A Haddad","year":"2021","unstructured":"Haddad A, Gazitt T, Feldhamer I et al (2021) Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther 23:44. https:\/\/doi.org\/10.1186\/s13075-021-02417-x","journal-title":"Arthritis Res Ther"},{"key":"5874_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"key":"5874_CR25","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/ard.2006.064808","volume":"66","author":"MS Heiberg","year":"2007","unstructured":"Heiberg MS, Kaufmann C, R\u00f8devand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK (2007) The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 66:1038\u20131042. https:\/\/doi.org\/10.1136\/ard.2006.064808","journal-title":"Ann Rheum Dis"},{"key":"5874_CR26","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s10067-017-3769-4","volume":"36","author":"MS Chimenti","year":"2017","unstructured":"Chimenti MS, Triggianese P, Conigliaro P, Tonelli M, Gigliucci G, Novelli L, Teoli M, Perricone R (2017) A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clin Rheumatol 36:2253\u20132260. https:\/\/doi.org\/10.1007\/s10067-017-3769-4","journal-title":"Clin Rheumatol"},{"key":"5874_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12026-014-8595-z","volume":"61","author":"L Costa","year":"2015","unstructured":"Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147\u2013153. https:\/\/doi.org\/10.1007\/s12026-014-8595-z","journal-title":"Immunol Res"},{"key":"5874_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","volume":"20","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, Fonti GL, Conigliaro P, Sunzini F, Scrivo R, Navarini L et al (2020) One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther 20:813\u2013821. https:\/\/doi.org\/10.1080\/14712598.2020.1761957","journal-title":"Expert Opin Biol Ther"},{"key":"5874_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2217\/ijr.12.63","volume":"7","author":"L Eder","year":"2012","unstructured":"Eder L, Chandran V, Gladman DD (2012) Gender-related differences in patients with psoriatic arthritis. Int J Clin Rheumatol 7:641\u2013649","journal-title":"Int J Clin Rheumatol"},{"key":"5874_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s002960100135","volume":"21","author":"R Queiro","year":"2001","unstructured":"Queiro R, Sarasqueta C, Torre JC, Tinture T, Lopez-Lagunas I (2001) Comparative analysis of psoriatic spondyloarthropathy between men and women. Rheumatol Int 21:66\u201368. https:\/\/doi.org\/10.1007\/s002960100135","journal-title":"Rheumatol Int"},{"key":"5874_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/ard.2008.092049","volume":"68","author":"M Wallenius","year":"2009","unstructured":"Wallenius M, Skomsvoll JF, Koldingsnes W, Rodevand E, Mikkelsen K, Kaufmann C et al (2009) Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 68:685\u2013689. https:\/\/doi.org\/10.1136\/ard.2008.092049","journal-title":"Ann Rheum Dis"},{"key":"5874_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105177","volume":"88","author":"MT Duru\u00f6z","year":"2021","unstructured":"Duru\u00f6z MT, Gezer HH, Nas K, K\u0131l\u0131\u00e7 E, Sarg\u0131n B, Kasman SA et al (2021) Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: a multi-center study. Joint Bone Spine 88:105177. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105177","journal-title":"Joint Bone Spine"},{"key":"5874_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.autrev.2015.11.002","volume":"15","author":"P Conigliaro","year":"2016","unstructured":"Conigliaro P, Chimenti MS, Ascolani M et al (2016) Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmun Rev 15:184\u2013190","journal-title":"Autoimmun Rev"},{"key":"5874_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025122","volume":"100","author":"P Conigliaro","year":"2021","unstructured":"Conigliaro P, Chimenti MS, Triggianese P et al (2021) Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: a STROBE-compliant study. Medicine (Baltimore) 100:e25122. https:\/\/doi.org\/10.1097\/MD.0000000000025122","journal-title":"Medicine (Baltimore)"},{"key":"5874_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0394632015615130","volume":"29","author":"P Triggianese","year":"2016","unstructured":"Triggianese P, Perricone C, Conigliaro P, Chimenti MS, Perricone R, De Carolis C (2016) Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure. Int J Immunopathol Pharmacol 29:65\u201375","journal-title":"Int J Immunopathol Pharmacol"},{"key":"5874_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102529","volume":"19","author":"P Conigliaro","year":"2020","unstructured":"Conigliaro P, D\u2019Antonio A, Pinto S et al (2020) Autoimmune thyroid disorders and rheumatoid arthritis: a bidirectional interplay. Autoimmun Rev 19:102529. https:\/\/doi.org\/10.1016\/j.autrev.2020.102529","journal-title":"Autoimmun Rev"},{"key":"5874_CR37","first-page":"804","volume":"35","author":"M Manara","year":"2017","unstructured":"Manara M, Caporali R, Favalli EG, Grosso V, Atzeni F, Sarzi Puttini P et al (2017) Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol 35:804\u2013809","journal-title":"Clin Exp Rheumatol"},{"key":"5874_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","volume":"47","author":"F Iannone","year":"2017","unstructured":"Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L et al (2017) Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 47:108\u2013114. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.008","journal-title":"Semin Arthritis Rheum"},{"key":"5874_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05742-3","author":"M Pombo-Suarez","year":"2021","unstructured":"Pombo-Suarez M, Sanchez-Piedra C, Garcia-Magall\u00f3n B, P\u00e9rez-G\u00f3mez A, Manrique-Arija S, Mart\u00edn-Dom\u00e9nech R et al (2021) Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-021-05742-3","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05874-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T16:18:14Z","timestamp":1641313094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05874-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5874"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05874-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"22 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding statement has been added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}